Summary
Several claims cannot be verified from the provided label excerpts (insufficient label support), and non-label statements (e.g., patent expiry, generic timing) are not present in the provided prescribing information. Multiple safety/clinical statements are therefore unsupported relative to the supplied text.
Category Scores
Accurate Statements
Lenvatinib is an orally available kinase inhibitor.
Label excerpts supplied do not explicitly state oral availability or kinase inhibitor description; determination is insufficient from provided text.
Lenvatinib is FDA-approved for the treatment of differentiated thyroid cancer.
Provided prompt text says excerpts are consistent with LENVIMA prescribing information including DTC; however the actual FDA label excerpts in the prompt for indications are not quoted.
Lenvatinib is FDA-approved for the treatment of renal cell carcinoma.
Provided prompt text says excerpts are consistent with LENVIMA prescribing information including RCC combinations; however the actual FDA label excerpts in the prompt for indications are not quoted.
Lenvatinib is FDA-approved for the treatment of hepatocellular carcinoma.
Provided prompt text says excerpts are consistent with LENVIMA prescribing information including HCC; however the actual FDA label excerpts in the prompt for indications are not quoted.
Serious side effects can occur with lenvatinib, including severe hypertension.
5.1 Hypertension: grade 3 and grade 4 hypertension occurred; label excerpt supports severe hypertension as possible.
Serious side effects can occur with lenvatinib, including heart problems.
5.2 Cardiac Dysfunction: serious and fatal cardiac dysfunction can occur.
Patients taking lenvatinib should have regular blood pressure checks.
Label excerpt provides hypertension occurrence data but does not explicitly state “regular blood pressure checks”; monitoring frequency is not provided in the excerpt.
Patients taking lenvatinib should be monitored for signs of bleeding.
5.12 Hemorrhagic Events describes serious/fatal hemorrhagic events but does not explicitly state monitoring for bleeding signs as a precaution instruction in the excerpt.
Patients taking lenvatinib should be monitored for signs of heart problems.
5.2 Cardiac Dysfunction describes serious/fatal cardiac dysfunction but the excerpt does not explicitly provide a “monitor for signs” instruction.
Unsupported Statements
Lenvatinib has broad-spectrum activity against various tyrosine kinases including VEGFR.
No mechanism-of-action kinase target specificity is provided in the supplied label excerpts.
Lenvatinib has broad-spectrum activity against various tyrosine kinases including FGFR.
No mechanism-of-action kinase target specificity is provided in the supplied label excerpts.
Lenvatinib has broad-spectrum activity against various tyrosine kinases including PDGFR.
No mechanism-of-action kinase target specificity is provided in the supplied label excerpts.
Lenvatinib has been shown to be effective in treating certain types of cancer that have become resistant to other treatments.
No label excerpt provided for efficacy statement regarding resistance/refractory disease.
In a clinical trial in advanced renal cell carcinoma, lenvatinib demonstrated improved progression-free survival compared to everolimus.
No efficacy comparison data (PFS vs everolimus) is provided in the supplied label excerpts.
Lenvatinib has a favorable safety profile compared to other tyrosine kinase inhibitors.
No comparative safety claim is provided in the supplied label excerpts.
The most common side effects of lenvatinib include diarrhea.
Label excerpt states diarrhea occurred in 49% and provides management, but does not explicitly call diarrhea among “most common” side effects.
The most common side effects of lenvatinib include hypertension.
Label excerpt provides hypertension incidence, but does not explicitly state it is among “most common side effects.”
The most common side effects of lenvatinib include fatigue.
No fatigue incidence/characterization is provided in the supplied label excerpts.
The most common side effects of lenvatinib include nausea.
No nausea incidence/characterization is provided in the supplied label excerpts.
The most common side effects of lenvatinib include weight loss.
No weight loss incidence/characterization is provided in the supplied label excerpts.
Serious side effects can occur with lenvatinib, including bleeding.
5.12 Hemorrhagic Events supports hemorrhagic events can occur, but the excerpt is not specific enough to directly support the simplified “bleeding” phrasing (and does not provide “bleeding” as a labeled serious side effect in the same way).
Patients taking lenvatinib should have regular blood pressure checks.
Hypertension data are provided, but explicit monitoring instruction frequency is not stated in the excerpt.
Patients taking lenvatinib should be monitored for signs of bleeding.
Hemorrhagic events are described, but the excerpt does not provide an explicit monitoring instruction for signs of bleeding.
Patients taking lenvatinib should be monitored for signs of heart problems.
Cardiac dysfunction risk is described, but the excerpt does not provide an explicit monitoring instruction for signs.
The patent for lenvatinib is expected to expire in 2029.
No patent/expiration timing information is included in the supplied prescribing information excerpts.
Generic versions of lenvatinib may become available earlier if manufacturers file for approval and receive approval from regulatory authorities.
No statements about patent expiry or generic availability timing are included in the supplied prescribing information excerpts.
Contradictions
Important Omissions
Details of dosing and administration (e.g., starting dose, dose adjustments, combination regimens) were not evaluated because the provided claims did not request dosing; however, the safety/monitoring claims also omit label-specific actions for several key warnings (e.g., proteinuria monitoring procedure using 24-hour urine; ECG/electrolyte correction for QT; thyroid function monitoring frequency; calcium monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most safety claims are broadly consistent with the existence of risks (hypertension, cardiac dysfunction, hemorrhagic events), but several monitoring and side-effect frequency/“most common” statements are unsupported by the supplied label excerpts; additionally, non-label patent/generic timing claims should not be treated as labeling-based medical information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple claims are unsupported by the provided prescribing information excerpts, including mechanism/target specificity, efficacy comparisons, comparative safety, several “most common” adverse effects (fatigue/nausea/weight loss), explicit monitoring instructions, and all patent/generic-timing statements.
Suggested Improvement
Restrict statements to those explicitly supported by the provided FDA label excerpts; remove or qualify non-label regulatory/patent/generic timing claims; replace generalized monitoring language with label-specific monitoring instructions and procedures as shown in the warnings (e.g., ECG/electrolytes for QT, proteinuria monitoring with 24-hour urine after 2+ dipstick, thyroid and calcium monitoring).